Analyst Ratings for Bicara Therapeutics Inc (BCAX)
BCAX Rating Summary
BCAX Price Target Summary
- Highest: $46.00 (Stifel)
- Lowest: $20.00 (Mizuho)
- Average: $33.77
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$33.77 (+97.8%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
Avg. $ Target:
$33.77 (+97.8%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | Morgan Stanley | Sean Laaman | New Coverage | Overweight (N/A) |
41.00 (N/A) |
16.78 (17.07) |
1.73% | Details |
| 8/18/2026 | BMO Capital | David Lebowitz | New Coverage | Outperform (N/A) |
35.00 (N/A) |
24.94 (17.07) |
-31.56% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
